Biotest AG: Biotest fights climate change through CO2-neutral production

DGAP-News: Biotest AG / Keyword(s): Miscellaneous

Biotest AG: Biotest fights climate change through CO2-neutral production

18.01.2022 / 07:00
The issuer is solely responsible for the content of this announcement.

PRESS RELEASE

Biotest fights against climate change thanks to CO2– neutral manufacturing

  • Climate neutrality achieved at the Dreieich site
  • Electricity purchased from renewable sources
  • Continuous reduction of energy consumption through targeted investments

Dreieich, January 18, 2022. Biotest AG is actively involved in the fight against climate change at the Dreieich site through targeted measures. The company, aware of its energy-intensive production and its impact on the environment, has been running a certified energy management system for years in order to systematically collect data, present it transparently and exploit the potentials optimization.

The company’s goal is to continuously reduce energy consumption and greenhouse gas emissions. Biotest AG publishes detailed data every year in its sustainability report.

When implementing optimization potential in a fully continuous production operation, weighing the potential, technical possibility and time feasibility is a major challenge.

“In 2021, we were able to reduce their electricity needs by 40% by replacing an air conditioning system. The annual electricity savings from this project alone are equivalent to the electricity consumption of around 50 households”, points out Dr Georg Floß, Chief Operating Officer (COO) of Biotest AG.

Other targeted measures are being implemented on an ongoing basis, such as the replacement of light bulbs, the installation of electric charging stations for cars, the optimization of the operating time of technical equipment and the use of refrigerants natural products for our cold stores.

For years, Biotest has been operating high-efficiency combined heat and power plants based on the principle of combined heat, power and cooling. This means that in addition to producing electricity for the company’s own needs, the waste heat is also used to air-condition buildings throughout the year.

In addition, the company is currently planning to install photovoltaic systems on company premises.

In order to make the remaining energy consumption climate-neutral despite all the measures listed, Biotest always obtains its electricity (approx. 30 million kWh) from renewable sources.

The remaining greenhouse gas emissions generated at the site are offset by voluntary investments in non-profit climate protection projects.

“In 2021, we promoted access to clean energy for rural communities in Vietnam by building biogas plants,” explains Dr. Georg Floß. “The power plants are built and used directly on site by the local population according to a simple, efficient and widely proven concept.”

This biogas program has already received several awards, including the renowned “Energy Globe Award”, the “Ashden Award” and the “Humanitarian Award”, and contributes to 11 United Nations social development goals.

Biotest AG is also currently supporting the local campaign to convert monostructural forest areas into climate-stable mixed forests in the municipal forest of Dreieich, thus once again demonstrating its environmentally friendly commitment.

About Biotest
Biotest is a supplier of plasma proteins and biological drugs. With an added value chain that extends from preclinical and clinical development to worldwide sales, Biotest specializes mainly in the fields of clinical immunology, hematology and critical care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 1,900 employees worldwide. Ordinary and preference shares of Biotest AG are listed on the Prime Standard of the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Email: [email protected]

Contact PR
Dirk Neumuller
Phone: +49-6103-801-269
Email: [email protected]

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Common Stock: Security ID No. 522720; ISIN DE0005227201
Preferred shares: Securities identification number 522723; ISIN DE0005227235
Registration: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Warning
This document contains forward-looking statements about the overall economic development as well as the business, earnings, financial condition and assets of Biotest AG and its subsidiaries. These statements are based on the company’s current plans, estimates, forecasts and expectations and are therefore subject to risks and elements of uncertainty which could cause actual developments to differ materially from those expected. Forward-looking statements speak only as of the time of posting. Biotest does not intend to update any forward-looking statements and assumes no obligation to do so.

18.01.2022 Broadcast of a Corporate News, transmitted by the DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP distribution services include regulatory announcements, financial/corporate news and press releases.
Archive at www.dgap.de

About Donald Martin

Check Also

The 6 Best Air Conditioners in 2022

When you buy through our links, Insider may earn an affiliate commission. Learn more. Central …